ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
Medexus Pharmaceuticals Inc

Medexus Pharmaceuticals Inc (MDP)

7,75
0,00
(0,00%)
Fermé 27 Novembre 10:00PM

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Statistiques et détails clés

Dernier
7,75
Prix Achat
7,80
Prix Vente
7,85
Volume échangé
-
0,00 Fourchette du Jour 0,00
7,75 Plage de 52 semaines 7,75
Cap du marché
Clôture Veille
7,75
Ouverture
-
Dernière Transaction
Dernière heure de transaction
Volume financier
-
VWAP
-
Volume moyen (3 m)
-
Actions en circulation
24 458 000
Rendement du Dividende
-
Ratio Cours sur Bénéfices
-289,66
Bénéfice par action (BPA)
-0,01
Chiffre d'affairess
113,05M
Bénéfice net
-214k

À propos de Medexus Pharmaceuticals Inc

Secteur
Pharmaceutical Preparations
Industrie
Blank Checks
Site Web
Siège social
Bolton, Gbr
Fondé
2013
Medexus Pharmaceuticals Inc est coté dans le secteur Pharmaceutical Preparations de la TSX Venture Exchange avec le ticker MDP. Le dernier cours de clôture d'Medexus Pharmaceuticals était de $7,75. Au cours de la dernière année, les actions de Medexus Pharmaceuticals ont été négociées dans une fourchette de prix de $ 7,75 à $ 7,75.

Medexus Pharmaceuticals compte actuellement 24 458 000 actions en circulation. La capitalisation boursière d'Medexus Pharmaceuticals est de $189,55 million. Medexus Pharmaceuticals a un ratio cours/bénéfice (ratio PE) de -289.66.

MDP Dernières nouvelles

Complete Response Letter Received from FDA for Treosulfan

TORONTO and CHICAGO and WEDEL, Germany, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSX: MDP) (OTCQX: MEDXF) and medac GmbH (“medac”) announced...

Medexus Appoints New Chief Financial Officer

TORONTO and CHICAGO, July 19, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSX: MDP) (OTCQX: MEDXF) is pleased to announce the appointment of Marcel Konrad...

Medexus Pharmaceuticals and medac GmbH enter into Licensing Agreement for First-in-Class Conditioning Agent, Treosulfan, in C...

TORONTO and CHICAGO and WEDEL, Germany, July 12, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSX: MDP) (OTCQX: MEDXF) today announced that it has entered...

Medexus Receives Notice of Compliance to Commercialize Treosulfan in Canada

TORONTO and CHICAGO, June 28, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSX: MDP) (OTCQX: MEDXF) today announced that it has received a Notice of...

Medexus Revenue Increases 43.5% to a Record US$79.7 Million for Fiscal 2021

Transformative licensing agreement for treosulfan in the U.S. completed February 2, 2021 Cash and cash equivalents of $18.7 million and available liquidity of $24.8 million at March 31, 2021...

Medexus Announces Graduation to the Toronto Stock Exchange

TORONTO and CHICAGO and MONTREAL, June 15, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSXV:MDP) (OTCQX: MEDXF) announced today that it has received final...

Medexus to Present at Raymond James Human Health Innovation Conference

TORONTO, CHICAGO and MONTREAL, June 14, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) announced today that it...

Medexus Schedules Fiscal Year 2021 Conference Call

TORONTO and CHICAGO and MONTREAL, June 11, 2021 (GLOBE NEWSWIRE) -- , June 11, 2021 - Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) today...

Medexus Strengthens Medical Affairs Team in Preparation for Planned Treosulfan Launch

TORONTO, CHICAGO and MONTREAL, June 10, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) today announced that it...

Medexus Announces Availability of Triamcinolone Hexacetonide in the United States

TORONTO and CHICAGO and MONTREAL, June 09, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) announced today that it...

PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
1007.757.757.7500CS
4007.757.757.7500CS
12007.757.757.7500CS
26007.757.757.7500CS
52007.757.757.7500CS
156007.757.757.7500CS
2603.5182.78301886794.249.751.4284376.77809156CS

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
NHT.UNexpoint Hospitality Trust
US$ 0,30
(1 900,00%)
4k
SCANLiberty Defense Holdiings LTD
$ 0,46
(820,00%)
19,72k
HPLHorizon Petroleum Ltd
 0,17
(325,00%)
10k
CPLCopper Lake Resources Ltd
$ 0,01
(100,00%)
20k
KIBKiboko Gold Inc
$ 0,02
(100,00%)
495k
RAC.PRiverwalk Acquisition Corp
$ 0,005
(-90,00%)
15k
ACAP.PAtlas One Capital Corporation
$ 0,005
(-66,67%)
8k
AMG.PAMG Acquisition Corp
$ 0,02
(-60,00%)
20k
EGTEguana Technologies Inc
$ 0,005
(-50,00%)
3k
DMDataMetrex AI Limited
$ 0,005
(-50,00%)
2,41M
BARUBaru Gold Corp
$ 0,045
(12,50%)
2,8M
MATEBlockmate Ventures Inc
$ 0,125
(-7,41%)
2,49M
DMDataMetrex AI Limited
$ 0,005
(-50,00%)
2,41M
FANFirst Atlantic Nickel Corp
$ 0,25
(28,21%)
2,27M
RHCRoyal Helium Ltd
$ 0,045
(28,57%)
2,05M
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

Delayed Upgrade Clock